China is the country with the highest number of diabetics worldwide, with around 141 million people suffering from the disease. By the year 2045, it is predicted that China will have around 174 million people with diabetes.

Death from diabetes

Diabetes is one of the leading causes of death worldwide, accounting for 1.5 million deaths in 2019. Diabetes at least doubles one’s chance of dying prematurely and many places in the world lack appropriate treatment options. The highest number of deaths from diabetes comes from the Western Pacific, where over 717,000 people died from the disease in 2021.

Obesity

One of the biggest risk factors for developing diabetes is being overweight or obese. Rates of obesity have increased in recent years in many countries around the world. In the United States, for example, it is estimated that around 32 percent of the adult population was obese in 2018, compared to 19 percent of the population in 1997.

In 2021, French Polynesia had the highest prevalence of diabetes worldwide, with around 27 percent of the population suffering from the disease. Diabetes mellitus, or simply, diabetes, refers to a group of metabolic disorders that cause high blood sugar levels. Diabetes can be prevented and treated though exercise, maintaining normal body weight, and healthy eating, but is usually managed with insulin injections.

Costs

As of 2021, there were almost 540 million people worldwide who had diabetes. With such a huge number of people suffering from this disease it is no surprise that spending on diabetes can be very high. It is estimated that the United States alone spent around 380 billion U.S. dollars on diabetes health expenditure in 2021. The countries with the highest spending per patient with diabetes include the United States, Switzerland, and Norway.

Death

Diabetes is among the leading ten causes of death worldwide, accounting for around 1.5 million deaths in 2019. Complications resulting from diabetes include chronic kidney disease, stroke, and cardiovascular disease. Risk of early death is at least doubled among those with diabetes. The Western Pacific reports the highest number of deaths from diabetes followed by the Middle East and North Africa.

In 2021, almost 17 percent of adults between the ages of 20 and 79 had diabetes in Mexico. Other selected countries with a high prevalence of diabetes that year included Turkey, Spain, and the United States. Diabetes is a metabolic disease that causes high blood sugar levels.

Diabetes worldwide

In 2021, an estimated 10.5 percent of the global adult population had diabetes. In concrete numbers, there were about 537 million diabetic adults (20-79 years) worldwide in 2021, and this total is predicted to grow to approximately 783 million by the year 2045.

Spending per patient

The country that spent the most on patients with diabetes in 2021 was the United States. At this time, providing for a diabetic patient here cost an average of almost 12 thousand U.S. dollars. Switzerland stood in second place, spending about 10,500 U.S. dollars per patient. In the same year, the ten countries by lowest average spending per person with diabetes were all African and Asian countries. The Democratic Republic of Congo had the lowest annual diabetes-related health expenditures per person, with about 156 U.S. dollars.

The country with the highest projected number of diabetics in 2045 is China, with some projected 174 million people between the ages of 20 and 79 suffering from diabetes. It is forecast that the number of adults with the condition in Pakistan will exceed that of the United States by 2045.

Number of diabetics worldwide

Diabetes is a condition that causes the pancreas to stop (or severely reduce) the production of insulin, a hormone needed to regulate blood sugar levels. Many people worldwide live with diabetes: in 2021, a total of about 537 million people had diabetes. This number is projected to reach an estimated 783 million by the year 2045.

Global diabetes costs

In 2021, 966 billion U.S. dollars were spent on diabetes-related healthcare treatment worldwide. Of 2021’s global total, almost 380 billion U.S. dollars were spent in the United States alone. Global healthcare expenditures for diabetes are expected to increase by 84 billion U.S. dollars by 2045.

This statistic shows the top 10 countries for number of children and adolescents aged 0 to 19 years with type 1 diabetes in 2021. In that year, the India topped the list with around the 229,400 children and adolescents, followed by the U.S. with 157,900.

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

This statistic shows the top 10 countries based on number of new cases of type 1 diabetes per 100,000 children aged 0 to 14 years, in 2021. Finland had the highest rate with 52.2 new cases per 100,000 children per year.

In 2021, almost 12 thousand U.S. dollars were spent per diabetic patient in the United States, making it the country with the highest average cost per person. Switzerland and Norway stood in second and third place, respectively, each spending over nine thousand U.S. dollars per patient.

Lowest spending countries

When viewing diabetes-related costs worldwide, it becomes apparent that there are significant disparities between countries. The ten countries with the lowest average annual diabetes-related health expenditures per person were all African and Asian countries. The Democratic Republic of the Congo stood at the top of the list in 2021, with an average spending of about 156 U.S. dollars per person. Other countries on this list included Bangladesh, Papua New Guinea, and the Soloman Islands.

Anti-diabetic revenue

Revenue generated by anti-diabetic products has increased as the number of diabetcis worldwide has risen. The largest pharmaceutical company, in terms of global anti-diabetic revenue, was Novo Nordisk in 2017. The company earned roughly 13.7 million U.S. dollars that year and is projected to generate about 21 million U.S. dollars in 2024.

ObjectiveDiabetes mellitus is the leading cause of death worldwide, and multiple risk factors associated with diabetes mortality.MethodsEmploying spatial statistics, we characterized the spatial distribution and patterns of diabetes mortality, and revealed the spatial relationship between diabetes mortality and 11 socioeconomic and environmental risk factors at the country level, from 1990 to 2019.ResultsGlobally, significantly high rates of diabetes mortality were primarily clustered in countries with limited land areas or located on islands, such as Fiji, Kiribati, Eswatini, and Trinidad and Tobago. Countries with weaker economic independence are more likely to have higher diabetes mortality rates. In addition, the impact of socioeconomic and environmental factors was significant at the country level, involving health expenditure, number of physicians, household and ambient air pollution, smoking, and alcohol consumption. Notably, the spatial relationship between diabetes mortality and ambient air pollution, as well as alcohol consumption, showed negative correlations. Countries with high diabetes mortality rates generally had lower levels of ambient air pollution and alcohol consumption.ConclusionThe study highlights the spatial clustering of diabetes mortality and its substantial variation. While many risk factors can influence diabetes mortality, it’s also essential to consider the level of these factors at the country level. Tailoring appropriate interventions based on specific national circumstances holds the potential to more effectively mitigate the burden of diabetes mortality.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising prevalence of diabetes, driven by unhealthy lifestyles and an aging population, is a major growth driver. Additionally, the low diagnosis rate presents an opportunity for market expansion. It is administered via different routes, including subcutaneous injection, insulin pumps, and insulin pens. According to the American Diabetes Association, approximately 26.8 million people in the United States have diabetes, and 7.3 million are undiagnosed. With increasing awareness and advancements in diagnostic tools, this number is expected to increase. These include continuous glucose monitoring systems, closed-loop insulin delivery systems, and non-pharmacological interventions such as diet and exercise. Furthermore, the growing burden of diabetes on healthcare systems and the need for effective management solutions are creating new opportunities for market participants. Overall, the market is poised for growth in the coming years, driven by these key trends and challenges.

What will be the Size of the Type 2 Diabetes Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapeutic compounds designed to manage and mitigate the effects of this chronic condition. With a global prevalence estimated to affect over 463 million people, primarily adolescents and young adults, the market exhibits significant growth due to the increasing burden of cardiovascular diseases, renal problems, and neurological complications associated with hyperglycemia. These complications include heart diseases, damage to the kidneys, and eye disorders, among others. Insulin and non-insulin medications, such as Jardiance, Tanzeum, and Trulicity, are commonly used to regulate blood sugar levels and alleviate symptoms like increased thirst, urination, fatigue, blurred vision, slow-healing wounds, and infections. Additionally, patients may experience tingling, numbness in feet and hands, and other neurological issues. Pharmaceutical companies continue to invest in research and development to address the unmet needs of this patient population and improve overall quality of life.

How is this Type 2 Diabetes Industry segmented and which is the largest segment?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. This condition affects adolescents, teenagers, and young adults, leading to increased thirst, urination, fatigue, blurred vision, slow-healing wounds, infections, tingling, numbness in feet and hands, yeast infections, darkened skin areas, and neurological problems. Over time, high blood glucose levels can lead to cardiovascular diseases, renal problems, and damage to the eyes. Insulin, a peptide hormone, plays a crucial role in regulating blood glucose levels. It interacts with insulin receptors on cell surfaces, facilitating the absorption of glucose into the cells. Insulin deficiency or insulin resistance leads to hyperglycemia, which can result in complications. The market for therapeutic compounds to manage Type 2 diabetes includes various drug classes such as insulin, thiazolidinediones, PPAR receptors agonists, Dipeptidyl Peptidase-4 Inhibitors, Alpha-Glucosidase Inhibitors, Sulfonylureas, Secretagogues, Biguanides, and others.

Moreover, these medications help improve glycemic control, reduce cardiovascular risk, and avoid hypoglycemia. Insulin is available in various forms, including human insulin, analog insulins, and inhaled insulin. Retail pharmacies and online pharmacies offer convenience for patients to access insulin and other diabetes medications. The market for Type 2 diabetes medications is expected to grow significantly due to the increasing prevalence of the disease and the need for effective disease management. Emerging economies are expected to offer significant growth opportunities due to increasin

Spain had the highest prevalence of diabetes in Europe among their adult population with 14.8 percent living with diabetes, as of 2021, Portugal followed with the second highest share at 13 percent. Conversely, Ireland was the country with the lowest prevalence of diabetes in Europe at four percent.

Diabetes-related deaths

The highest number of diabetes-related deaths in Europe, at almost 173 thousand, was recorded Italy in 2021. Germany and UK followed, with roughly 151.5 and 140.8 thousand deaths, respectively.

Diabetes risk factors in Europe

One of the major contributing factors to type 2 diabetes is being overweight or obese. As of 2020, Greece had the highest share of overweight population across Europe, with 40.8 percent. The lack of sports and exercise is also another risk factor. As of 2022 Portugal was the European country with the highest share of people never exercising or engaging in sports, with 73 percent.

Ireland: Diabetes prevalence, percent of population ages 20-79: The latest value from 2021 is 3 percent, a decline from 5.2 percent in 2011. In comparison, the world average is 8.60 percent, based on data from 195 countries. Historically, the average for Ireland from 2011 to 2021 is 4.1 percent. The minimum value, 3 percent, was reached in 2021 while the maximum of 5.2 percent was recorded in 2011.

*(Age-standardised incidence rates per 100,000 individuals per year with 95% confidence intervals. † For cells labeled as NA, 95% CIs could not be estimated as there was only 1 data point).

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

ObjectiveTo produce estimates of the global burden of type 2 diabetes mellitus (T2DM) caused by high body mass index (high BMI) and its impact for 2021 and projections for 2045.MethodsWe downloaded data from the Global Burden of Disease Study 2021(GBD 2021) to estimate the disease burden of T2DM caused by high BMI. Secondary analyses were performed by year, age, gender, region, and socio-demographic index (SDI).ResultsGlobally, the all-ages number of T2DM-related deaths has increased significantly from 238.1 thousand to 723.7 thousand, representing a 203.9% increase since 1990. And the all-ages number of T2DM-raleted DALYs has raised from 10.4 million to 39.3 million, increased by 276.7% from 1990. The burden was expected to continue to increase to 1296.7 thousand by 2045 for all-ages number of deaths, and 85.5 million by 2045 for all-ages number of DALYs. The curves of T2DM-related burden showed an intersection for different genders around the age of 60, beyond which women exhibit a higher burden, compared to men. The disease burden of T2DM caused by high BMI shows a significant upward trend across all SDI groups, with a heavier burden on women, especially in the postmenopausal female population. In 2021, among the 204 countries and territories, the top 3 largest number of T2DM-related burden caused by high BMI occurred in China, India, and United States. The top three countries with highest T2DM-related rate caused by high BMI were Fiji, Marshall Islands, and Kiribati.ConclusionOur study reveals that the disease burden of T2DM caused by high BMI is significantly increasing and is expected to continue rising in the future. Women bear a heavier burden, particularly postmenopausal women, and there are significant differences in the disease burden across different geographical regions, and socioeconomic statuses. Targeted considerations and specific strategies are essential to address these disparities, thereby improving public health and reducing the burden.

BackgroundGestational Diabetes Mellitus (GDM) is defined as the type of hyperglycemia diagnosed for the first-time during pregnancy, presenting with intermediate glucose levels between normal levels for pregnancy and glucose levels diagnostic of diabetes in the non-pregnant state. We aimed to systematically review and meta-analyze studies of prevalence of GDM in European countries at regional and sub-regional levels, according to age, trimester, body weight, and GDM diagnostic criteria.MethodsSystematic search was conducted in five databases to retrieve studies from 2014 to 2019 reporting the prevalence of GDM in Europe. Two authors have independently screened titles and abstracts and full text according to eligibility using Covidence software. A random-effects model was used to quantify weighted GDM prevalence estimates. The National Heart, Lung, and Blood Institute criteria was used to assess the risk of bias.ResultsFrom the searched databases, 133 research reports were deemed eligible and included in the meta-analysis. The research reports yielded 254 GDM-prevalence studies that tested 15,572,847 pregnant women between 2014 and 2019. The 133 research reports were from 24 countries in Northern Europe (44.4%), Southern Europe (27.1%), Western Europe (24.1%), and Eastern Europe (4.5%). The overall weighted GDM prevalence in the 24 European countries was estimated at 10.9% (95% CI: 10.0–11.8, I2: 100%). The weighted GDM prevalence was highest in the Eastern Europe (31.5%, 95% CI: 19.8–44.6, I2: 98.9%), followed by in Southern Europe (12.3%, 95% CI: 10.9–13.9, I2: 99.6%), Western Europe (10.7%, 95% CI: 9.5–12.0, I2: 99.9%), and Northern Europe (8.9%, 95% CI: 7.9–10.0, I2: 100). GDM prevalence was 2.14-fold increased in pregnant women with maternal age ≥30 years (versus 15-29 years old), 1.47-fold if the diagnosis was made in the third trimester (versus second trimester), and 6.79- fold in obese and 2.29-fold in overweight women (versus normal weight).ConclusionsIn Europe, GDM is significant in pregnant women, around 11%, with the highest prevalence in pregnant women of Eastern European countries (31.5%). Findings have implications to guide vigilant public health awareness campaigns about the risk factors associated with developing GDM.Systematic Review RegistrationPROSPERO [https://www.crd.york.ac.uk/PROSPERO/], identifier CRD42020161857.

Age-standardized death rate of T2DM from 2020 to 2030.

This is Stata replication code for: "Rural-Urban Disparities in Hypertension and Diabetes Care in 45 Low- and Middle-Income Countries: A Pooled Analysis of Nationally Representative, Individual-Level Data"

The prevalence of multiple age-related cardiovascular disease (CVD) risk factors is high among individuals living in low- and middle-income countries. We described receipt of healthcare services for and management of hypertension and diabetes among individuals living with these conditions using individual-level data from 55 nationally representative population-based surveys (2009–2019) with measured blood pressure (BP) and diabetes biomarker. We restricted our analysis to non-pregnant individuals aged 40–69 years and defined three mutually exclusive groups (i.e., hypertension only, diabetes only, and both hypertension-diabetes) to compare individuals living with concurrent hypertension and diabetes to individuals with each condition separately. We included 90,086 individuals who lived with hypertension only, 11,975 with diabetes only, and 16,228 with hypertension-diabetes. We estimated the percentage of individuals who were aware of their diagnosis, used pharmacological therapy, or achieved appropriate hypertension and diabetes management. A greater percentage of individuals with hypertension-diabetes were fully diagnosed (64.1% [95% CI: 61.8–66.4]) than those with hypertension only (47.4% [45.3–49.6]) or diabetes only (46.7% [44.1–49.2]). Among the hypertension-diabetes group, pharmacological treatment was higher for individual conditions (38.3% [95% CI: 34.8–41.8] using antihypertensive and 42.3% [95% CI: 39.4–45.2] using glucose-lowering medications) than for both conditions jointly (24.6% [95% CI: 22.1–27.2]).The percentage of individuals achieving appropriate management was highest in the hypertension group (17.6% [16.4–18.8]), followed by diabetes (13.3% [10.7–15.8]) and hypertension-diabetes (6.6% [5.4–7.8]) groups. Although health systems in LMICs are reaching a larger share of individuals living with both hypertension and diabetes than those living with just one of these conditions, only seven percent achieved both BP and blood glucose treatment targets. Implementation of cost-effective population-level interventions that shift clinical care paradigm from disease-specific to comprehensive CVD care are urgently needed for all three groups, especially for those with multiple CVD risk factors.

Diabetes prevalence is on the rise in the Middle East. In countries of the Gulf region—Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates—prevalence rates are among the highest in the world. Further, Egypt now ranks as one of the top 10 countries in the world for high number of people with diabetes. Medical nutrition therapy is key to optimal management of diabetes. Patient adherence to nutritional guidance depends on advice that is tailored to regional foods and cultural practices. In 2012, international experts created a transcultural Diabetes Nutrition Algorithm (tDNA) for broad applicability. The objective of this current project was to adapt the algorithm and supportive materials to the Middle East region. A Task Force of regional and global experts in the fields of diabetes, obesity, and metabolic disorders met to achieve consensus on Middle East-specific adaptations to the tDNA. Recommendations, position statements, figures, and tables are presented here, representing conclusions of the tDNA-Middle Eastern (tDNA-ME) Task Force. Educational materials can be used to help healthcare professionals optimize nutritional care for patients with type 2 diabetes. The tDNA-ME version provides evidence-based guidance on how to meet patients' nutritional needs while following customs of people living in the Middle Eastern region.